

# Hemolytic Jaundice In Newborns

Tolipova Noila Kudratovna<sup>1</sup>, Latipova Shakhnoza Akbarbekovna<sup>2</sup>, Azimova Sevara Bakhodirovna<sup>3</sup>

<sup>1</sup>Candidate of Medical Sciences, Associate Professor of the Department of Pediatrics and Family Medicine at the Tashkent Medical Academy Email: [noilatolipovamed@gmail.com](mailto:noilatolipovamed@gmail.com)

<sup>2</sup>candidate of medical science, senior lecturer of the department of pediatric diseases and family medicine at the Tashkent Medical Academy. Email: [Shakhnozatma@gmail.com](mailto:Shakhnozatma@gmail.com)

<sup>3</sup>doctor of medical science, associate professor of the Department of Normal and Pathological Physiology, at the Tashkent Medical Academy Email: [azimovasevara777@gmail.com](mailto:azimovasevara777@gmail.com)

DOI: 10.47750/pnr.2022.13.S07.193

## Abstract

Neonatal jaundice that occurs in ABO or Rhesus isoimmunisation has been recognized as one of the major risk factors for development of severe hyperbilirubinemia and bilirubin neurotoxicity.

**Keywords:** hemolytic jaundice, ABO/Rh isoimmunisation, unspecific etiology, hyperbilirubinemia

**Introduction.** Neonatal jaundice is a common phenomenon during the first week of postnatal life affecting almost two thirds of term newborns [1, 2]. The mechanism of neonatal hyperbilirubinemia is multifactorial, comprising primarily processes that contribute to increased bilirubin load, or diminished bilirubin clearance [1-3]. The former may result from causes that potentiate bilirubin production and the enterohepatic circulation, whereas the latter may result from immature conjugative capacity, and/or impaired hepatic uptake or excretion [1,3]. It has been shown that the imbalance between bilirubin production and conjugation plays an important role in the mechanism of neonatal bilirubinemia [4]. Although both genetic and environmental factors may contribute to the development of neonatal hyperbilirubinemia, the importance of genetically determined conditions has been increasingly recognized [5,8].

Bilirubin overproduction that occurs in ABO, Rhesus or minor blood group incompatibilities with a positive direct antiglobulin test has been recognized as one of the major risk factors for development of severe hyperbilirubinemia in infants of 35 or more weeks' gestation [9]. Isoimmune hemolytic disease has been included in the "neurotoxicity risk factors" list aimed to emphasizing main risk factors associated with brain damage in severe hyperbilirubinemia [10]. Lower phototherapy and exchange transfusion threshold levels are recommended in isoimmune hemolytic disease in order to prevent acute manifestations of bilirubin toxicity that might evolve into chronic and permanent neurological sequelae- kernicterus. Features of the latter include athetoid cerebral palsy, hearing loss, and intellectual handicaps, visual and dental problems [1,5,7].

In a previous study we showed a prevalence of 14.43% of hemolysis in a group of infants with indirect hyperbilirubinemia in a two-year period. We also showed a high prevalence (44.37%) of jaundice of unidentified etiology; the group included: exaggerated physiological jaundice, early and late onset breast-milk jaundice, and no identifiable etiology [10].

The aim of our study was to investigate clinical and laboratory parameters associated with hemolytic jaundice due to Rh and ABO incompatibility and compare results with the group of unspecific jaundice with unidentifiable etiology.

## Material and Methods

The study group included 167 newborns treated with neonatal hyperbilirubinemia. 41 patient (24.6%) who presented with ABO or Rhesus type hemolytic disease of the newborn, and 126 patients (75.4%) who were treated with unspecific neonatal jaundice (Table 1). Medical records were reviewed extensively to exclude clinical signs and symptoms that could increase the extent of jaundice such as: cephalhaemathoma, bruising, ecchymoses, lacerations, sepsis, prematurity, hypothyroidism, CNS hemorrhage, intestinal atresia or stenosis, hypertrophic pyloric stenosis, delayed meconium passage, G6PD deficiency and Down syndrome [3, 5]. The following laboratory tests were performed: full blood count and smear, hemoglobin and hematocrit levels, reticulocyte count, serum levels of total, indirect and direct bilirubin, serum aminotransferases- aspartat transaminase (AST) and alanin transaminase (ALT), glucose-6-phosphate dehydrogenase (G6PD) quantitative test, maternal and neonatal blood groups, direct antiglobulin (Coombs) test. The study also included evaluation of the day at which bilirubin level reached peak, duration of the hyperbilirubinemia, as well as the first and second control bilirubin measurement where clinically indicated. In some cases, tests such as C-reactive protein (CRP), blood, cerebrospinal fluid and other cultures, thyroid function tests as well as ultrasonography of the central nervous system and radiograms were performed to exclude other etiologies of jaundice [3, 9, 10]. Hemolytic etiology of jaundice was considered in cases of Coombs positive ABO or Rh blood group incompatibility. Undefined etiology of jaundice was defined as previously described [2].

**Table 1 Study group**

No	Etiology group	Number of patients	Percentage (%)
1.	Hemolysis (ABO and Rh incompatibility)	41	24.6
2.	Unspecific jaundice	126	75.4
Total		167	100

Full blood count was analyzed using the Sysmex K-4500 automated hematology analyzer (Minnesota, USA); light microscopy was involved when analyzing blood smear and reticulocytes. Total serum bilirubin and fractions were obtained using photometric chemistry analyzer Kodak Ectachem 250 (Rochester, NY) [4]. G6PD activity in erythrocytes was determined spectrophotometrically. The rate of absorbance change was measured at 340 nm, due to the reduction of nicotinamide adenine dinucleotide phosphate (NADP) to NADPH when a sample was incubated with G6P (Humananalyser 3000, Germany). G6PD activity was calculated in relation to erythrocyte count. Commercially available kits (AMS U.K. Ltd, East Sussex, U.K.) were used. Values of  $272 \pm 27$  mU/109 erythrocytes were considered normal, and results were interpreted as percentage of the normal G6PD activity [5, 6].

## Results

The subject group consisted of 167 patients with indirect neonatal hyperbilirubinemia including 41 patients (24.6%) with ABO or Rhesus type hemolytic disease of the newborn, and 126 patients (75.4%) with unspecific neonatal jaundice (Table 1).

Laboratory parameters that were analyzed from full blood count were: 1) Hemoglobin (Hb), 2) Erythrocytes (Er), and 3) Hematocrit (Hct).

In the group of newborns with ABO/Rh incompatibility significantly lower mean values of hemoglobin ( $p = 0.038$ ), erythrocytes ( $p = 0.0023$ ) and hematocrit ( $p = 0.037$ ) were noted compared to the group of jaundice with unspecific etiology (Table 2).

**Table 2 Analyses from full blood count**

Groups	N	mean $\pm$ SD	min-max	t-value, p
Hb (g/l)				
1.	41	155.02 $\pm$ 30.3	74 - 218	t=2.09 p=0.038*
2.	126	165.36 $\pm$ 26.5	105 - 224	
Er (x10 <sup>12</sup> )				
1.	41	4.29 $\pm$ 0.8	2.05 - 5.81	t=3.09 p=0.0023*

2.	126	4.67 ± 0.6	3.27 – 6.58	
Htc (%)				
1.	41	41.35 ± 8.9	18.9 – 61.9	t=2.11 p=0.037*
2.	126	44.26 ± 7.2	28.4 – 64.6	

\*p < 0.05; t- Student t test; N- number of patients; SD- standard deviation; p- probability value.

Mean reticulocyte count was highly significantly higher (p = 0.000036) in the group of ABO/Rh incompatibility (27.88 ± 26.4 vs. 11.94 ± 7.4). In this group of newborns, the jaundice appeared significantly earlier (p < 0.01) compared to the group of jaundice with unidentified etiology (2.63 ± 2.4 vs. 4.02 ± 2.5 days). Duration of the bilirubin peak was significantly longer (p = 0.036) in the group of unspecific jaundice (15.03 ± 25.7 vs. 10.22 ± 9.02 days) (Table 3).

**Table 3 Analyses of bilirubin**

Groups	N	mean±SD	median	min-max	t-value, p
Ret					
1.	41	27.88 ± 26.4	22.0	2 - 121	Z=4.13 p=0.000036**
2.	126	11.94 ± 7.4	11.0	1 - 39	
Day of bilirubin peak					
1.	41	2.63 ± 2.4	2.0	1 – 14	Z=5.78 p=0.000**
2.	126	4.02 ± 2.5	3.0	2 – 14	
Peak bilirubin level (µmol/l)					
1.	41	379.76 ± 133.5	364.0	158 – 801	Z=1.95 p=0.052 NS
2.	126	333.44 ± 91.1	324.0	107 - 598	
Duration of the bilirubin peak (days)					
1.	41	10.22 ± 9.02	6.0	1 – 37	Z=2.09 p=0.036*
2.	126	15.03 ± 25.7	9.0	2 - 279	
First control bilirubin (µmol/l)					
1.	40	274.2 ± 124.9	235.5	96 – 682	Z=1.87 p=0.062 NS
2.	112	227.39 ± 80.7	211.5	60 - 473	
Second control bilirubin (µmol/l)					
1.	24	227.46 ± 83.4	206.0	111 – 437	Z=0.76 p=0.448 NS
2.	48	221.92 ± 48.3	228.5	51 - 314	

\*p < 0.05;

\*\*p<0,01 Z (Mann-Whitney U test); N- number of patients; SD- standard deviation; p- probability value; NS- not significant.

Newborns from the ABO/Rh incompatibility group compared to the group of newborns with unspecific jaundice had insignificantly higher peak bilirubin level (p = 0.052), as well as insignificantly higher levels at the first (p = 0.062) and second (p=0.448) control bilirubin measurements (Table 3).

Levels of hepatic transaminases (AST and ALT) were not found to depend significantly on the etiology of jaundice (Table 4).

**Table 4 Amynotransferases- AST and ALT**

Groups	N	mean±SD	median	min-max	t-value, p
AST (U/l)					
1.	41	62.51 ± 47.8	51.0	22 – 317	Z=0.067 p=0.95 NS
2.	125	58.62 ± 32.2	52.0	21 - 218	
ALT (U/l)					
1.	41	33.09 ± 23.5	28	3 – 109	Z=0.19 p=0.85 NS
2.	125	32.27 ± 24.5	30	3 - 170	

Z (Mann-Whitney U test); N- number of patients; SD- standard deviation; p- probability value; NS- not significant.

Treatment of jaundice was performed according to current protocols with continuous phototherapy/and or exchange transfusion [1, 3, 9]. The bulk of the cases 161 (96.4%) were managed conventionally using double surface blue light phototherapy lamps at wave length of 460 nm. Six patients (3.6% of the whole group, and 14.6% of the hemolytic etiology group) were treated with exchange transfusion (ECT) out of which 4 (two thirds) patients presented with ABO incompatibility, and the remaining 2 with Rh incompatibility.

## Discussion

In this study we aimed to investigate clinical and laboratory parameters associated with hemolytic jaundice due to Rh and ABO incompatibility and compare results with a group of infants with jaundice of unspecific origin. We proved statistically significant correlations of all relevant laboratory parameters between the two groups. In a previous study, we found a high prevalence of jaundice of undefined etiology (44.37%), ascribed to cases where despite intensive workout, no identifiable cause or contributing factor for jaundice could be found [1]. We speculated an imbalance between bilirubin production and conjugation to be the key concept of jaundice in this group based on lack of history, clinical and laboratory data that would indicate another mechanism of jaundice [4,6]. This group was used as a reference for comparison of clinical and laboratory parameters. Blood group incompatibility induced haemolysis (either ABO or Rh) has been identified as one of the risk factor for both severe hyperbilirubinemia and bilirubin neurotoxicity in infants of 35 or more weeks' gestation [9, 10]. Moreover, it has been postulated that synergistic effect of DAT positive isoimmune hemolytic disease and severe hyperbilirubinemia potentiate bilirubin-induced neurotoxicity [2]. Lower phototherapy and exchange transfusion threshold levels have been recommended in isoimmune hemolytic disease to prevent manifestations of bilirubin encephalopathy, also a pre-discharge risk assessment and early post-discharge follow up [9, 10]. We found significantly lower mean values of hemoglobin, erythrocytes and hematocrit and highly significantly higher values of reticulocytes in the group of ABO/Rh incompatibility compared to the group of jaundice of unspecific etiology. This confirms that hemolysis is the main component of jaundice in this group of patients and is consistent with findings from other studies [3, 8]. In this group of newborns, the jaundice appeared significantly earlier compared to the group of jaundice with unidentified etiology (at median age of 2 days). Although peak bilirubin level in the hemolytic group was insignificantly higher compared to the other group, a clear tendency to earlier rise and higher values of serum bilirubin were noted. Duration of the bilirubin peak was significantly longer in the group of unspecific jaundice. We can speculate that this finding might reflect differences in response to phototherapy in both groups, nevertheless, other impacts such as different mechanisms of jaundice, dissimilar biological progress of jaundice or stringency to phototherapy cannot be excluded. Levels of hepatic transaminases (AST and ALT) were not found to depend significantly on the etiology of jaundice. Although analysis of transaminases is performed on a regular basis in our hospital practices when evaluating an infant for jaundice, it is of little clinical value in cases of unconjugated hyperbilirubinemia and cannot be readily recommended. According to an evidence-based review on neonatal hyperbilirubinemia, the majority of kernicterus cases occurred in infants with a bilirubin level higher than 20 mg/dL (342 umol/l) [29]. It is clear that our hemolysis cases with mean peak bilirubin levels of  $379.8 \pm 133.5$  umol/l are eligible for the neurotoxic effects of the high bilirubinemia especially the ones towards the higher end of the spectrum (maximum of 801 umol/l) and are candidates for long-term neurodevelopmental follow-up. Therefore, clinicians' awareness of potential treats and harms that might be associated with isoimmunisation is vital.

**In conclusion**, laboratory profile in ABO and Rh isoimmunisation cases depicts hemolytic mechanism of jaundice. This group of patients is associated with a significant risk for early and severe hyperbilirubinemia and is eligible for long-term neurodevelopmental follow-up. Hematological parameters together with blood grouping are simple diagnostic methods that assist the etiological diagnosis of neonatal hyperbilirubinemia.

## References

1. Racha Khalaf, Claudia Phen, Sara Karjoo and Michael Wilsey Cholestasis beyond the neonatal and Infancy Periods // *Pediatr Gastroenterol Hepatol Nutr.* — 2016. — 19(1). — P. 1–11/
2. Naureen Memon, Barry Weinberger, Thomas Hegyi and Lauren M Aleksunes Inherited Disorders of Bilirubin Clearance // *Pediatr Res.* — 2016. — 79(3). — P. 378–386.
3. Surkov A.I. Differential diagnosis of hepatolienal syndrome in children // *Pediatric practice. Gastroenterology.* - 2013. - September. — P. 7–15.17. Jagadisan B., Srivastava A. Child with Jaundice and Pruritus: How to Evaluate?// *Indian J Pediatr.* — 2016. — 83(11). — P. 1311–1320.
4. Eleonora Druve Tavares Primary sclerosing cholangitis in children and adolescents // *Arq. Gastroenterol.* — 2017. — Vol. 54 . — №.4.
5. Farwell G.G. The clinicopathological spectrum of drug-induced liver diseases. *Drug-induced liver diseases* // Churchill Livingstone. — London, 1994. — P. 101
6. Molochkova O.V., Kovalev O.B., Uchaikin V.F., Konev V.A., Snetkova Yu.S. Drug-induced hepatitis in children // *Children's infections.* - 2017. - Volume 16, No. 1. — pp. 42–50.
7. I. N. Zakharova, A. N. Goryainova, I. N. Kholodova, and I. D. Maykova, Belenovich E.V., Tambieva E.V., Bolbikova E.V., Melenkina A.N.,
8. Khudyakova A.A. Differential diagnosis of jaundice in young children // *Medical Council. Gastroenterology.* — 2016. — No. 7. — pp. 56–65.
9. Strokova T.V. Hereditary metabolic diseases of the liver // *Pediatrics. Special issue "School for practicing doctors".* - 2012. - S. 60-65.
10. Strokova T.V., Bagaeva M.E., Matinyan I.A. Deficiency of lysosomal acid lipase // *BC. Pediatrics.* - 2017, No. 19. - pp. 1346–1351.